Gonadorelin

Status

No approved product. Previously FDA-approved as Factrel (NDA 018123, diagnostic use) and Lutrepulse (NDA 019687, primary hypothalamic amenorrhoea); Drugs@FDA lists all five products as discontinued (retrieved 25 October 2026), so no marketed FDA-approved product was found. Discontinuation on its own is not a safety withdrawal. Other countries were not verified for this entry. Compounded preparations are not FDA-approved.

What it is

Synthetic GnRH used diagnostically and in some maintenance protocols.

What published research measured

Synthetic gonadotropin-releasing hormone, identical to the endogenous decapeptide. Its pharmacology includes a central fact about this class: the pituitary responds to pulsatile GnRH by releasing gonadotropins, but responds to continuous exposure by downregulating and shutting the axis down. Pulsatile administration by pump has established use in inducing ovulation and in hypogonadotropic hypogonadism; continuous administration produces the opposite of the intended effect. Its half-life is a matter of minutes. It previously held FDA approval as a diagnostic agent for evaluating pituitary gonadotropic function, and current supply in the United States is through compounding.

Source

Pulsatile GnRH administration literature in hypogonadotropic hypogonadism

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.